SLSBio(Specialty Lab Solution Bio)
에스엘에스바이오 · 246250
Industrials Commercial Services · KOSDAQ
Market cap US$21.9M (₩30.2B)
Overview
SLSBio provides pharmaceutical quality-testing services, laboratory tests that verify whether a drug meets the safety and efficacy standards required by Korean regulators, and also supports drug-discovery research and develops in-vitro diagnostic test kits.
Its clients include pharmaceutical importers and manufacturers that lack their own testing facilities or expertise. Listed on KOSDAQ, Korea's tech and small-cap board, the company is officially designated by Korea's Ministry of Food and Drug Safety as an authorized contract-testing institution, a status that creates high barriers to entry for new competitors in this field.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$6.5M
- FY2024US$6.1M
- FY2025US$2.9M
Operating profit
- FY2023US$747.1K
- FY2024US$208.4K
- FY2025−US$3M
Net income
- FY2023US$1M
- FY2024US$243.2K
- FY2025−US$3.6M
Key ratios (FY2025)
Why it matters
The company holds a formal designation from Korea's Ministry of Food and Drug Safety (식품의약품안전처) as an authorized pharmaceutical quality-testing institution, a government-granted status required to perform contract testing on behalf of importers.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?